Experiential Education Facilitation

Jessica Power, B.Sc.(Pharm.), ACPR Experiential Education Facilitator and Clinical Pharmacist, Victoria General Hospital This presentation will be an introduction to EEF role, a discussion of novel precepting models, as well as strategies to face inherent challenges. We will look at OEE changes to rotations including

This presentation will be an introduction to EEF role, a discussion of novel precepting models, as well as strategies to face inherent challenges. We will look at OEE changes to rotations including description of the new IPPE II PHRM 272 rotation activities and work through three difficult student situations.

Handout

Boning Up on Mineral Metabolism and Anemia in Chronic Kidney Disease

Disease Stephanie Tarasoff, BScPharm, ACPR Clinical Pharmacist, Royal Jubilee Hospital

This presentation will be a review of two complex aspects of chronic kidney disease: bone mineral metabolism and anemia of chronic kidney disease. Pathophysiology, pharmacotherapy, monitoring parameters, and clinical pearls will be reviewed.

Handout

Let’s Explore Dyslipidemia Guidelines, Etc.

Arden Barry, BSc, BSc(Pharm), PharmD, ACPR Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services; Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia; Associate Member, Department of Family Practice, Faculty of Medicine, University of British Columbia

The treatment of dyslipidemia is controversial despite a plethora of available published evidence. This has led to the development of multiple dyslipidemia guidelines— while these documents differ with respect philosophy and complexity, they are more similar than they are different. This presentation aims to explore three recently published dyslipidemia guidelines with the goal of deriving a few pragmatic considerations that participants can apply in practice.

Handout: https://cshp-bc.com/events/handouts/2016/island/CSHP-BC%20VIEE_Barry_Dyslipidemia%20Handout.pdf

Managing NSTE-ACS: One Beat at a Time

Amy Nunley, BScPh, ACPR

Review of medications used to manage NSTEACS.

Objectives:

Describe at least 4 risk factors for NSTE-ACS

List at least 3 medications that have mortality benefit after NSTE-ACS

List target doses and monitoring parameters for each of:

  • Antiplatelets (Acetylsalicylic Acid [ASA], clopidogrel, ticagrelor)
  • ACE-inhibitors
  • Beta-blockers
  • Statins

Handout

RSV program in Northern Health and Neonatal Hyperbilirubinemia – giving the green light for treating the yellow fellow

Julie Gagnon, Pharmacist – Mat/Child, UHNBC Prince George

Review of the RSV program in Northern Health and Neonatal Hyperbilirubinemia.

 

RSV program in NH – Objectives:

Identify differences in seasonal eligibility across British Columbia

Determine eligibility of infants for RSV prophylaxis based on current program standards

Understand process for both initial dosing and subsequent administration

Answer common questions related to administration including dosing and eligibility

 

Neonatal Hyperbilirubinemia – Objectives:

Review bilirubin metabolism

Potential consequences of high bilirubin

Phototherapy overview

Risk factors associated with prematurity

Evaluating drug safety and alternatives

 

Handout

Review of the updated Canadian Cardiovascular Society guidelines for the management of dyslipidemia

Dr. Arden Barry, BSc, BScPharm, PharmD, ACPR

Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services

Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia

Objectives:

Identify recently published guidelines for the treatment of dyslipidemia

Review key clinical trials in the management of dyslipidemia published since 2012

Review the key recommendaEons relevant to pharmacists from the (to be published) updated Canadian Cardiovascular Society guidelines for the management of dyslipidemia.

Handout